🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

15 recruiting trials

for Newly Diagnosed Peripheral T-cell Lymphoma

Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma NCT06583083Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Sintilimab with P-GEMOX Regimen, P-GEMOX Regimen A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL NCT05931263Phase 31 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: C-BEAM Regimen, BEAM Regimen Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) NCT05976997Phase 21 site📍 Wuhan Liling Zhang · Tests: Duvelisib, Chidamide Genotype-guided Treatment in Newly Diagnosed PTCL NCT05675813Phase 1, Phase 21 site📍 Shanghai Ruijin Hospital · Tests: CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab, standard CHOP A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study NCT06630091Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma NCT06824883Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Immunochemotherapy Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type NCT05477264Phase 21 site📍 Seoul Won Seog Kim · Tests: Tislelizumab Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) NCT06390319Phase 24 sites📍 San Diego📍 Charlotte📍 Tulsa St. Jude Children's Research Hospital · Tests: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL NCT07678229Phase 31 site📍 Shanghai Rong Tao · Tests: GELAD regimen, MEDA regimen, LEAP regimen, High-dose methotrexate, Autologous Hematopoietic Stem Cell Transplantation Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype NCT06947967Phase 31 site📍 Guangzhou Chipscreen Biosciences, Ltd. · Tests: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Tucidinostat, Placebo PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma NCT05662540NA1 site📍 Shanghai Ruijin Hospital · Tests: Positron Emission Tomography/Magnetic Resonance (PET/MR) Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma NCT05833893Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: XPO1 inhibitor Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. NCT03964480n/a6 sites📍 Stanford📍 Bari📍 Palermo Associazione Angela Serra per la ricerca sul cancro A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) NCT04365036Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT) Golidocitinib Plus CHOP in Newly Diagnosed PTCL NCT06739265Phase 1, Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Golidocitinib plus CHOP
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy